KR101434706B1 - 미립자 유성 현탁액을 포함하는 의약 조성물 - Google Patents

미립자 유성 현탁액을 포함하는 의약 조성물 Download PDF

Info

Publication number
KR101434706B1
KR101434706B1 KR1020097019114A KR20097019114A KR101434706B1 KR 101434706 B1 KR101434706 B1 KR 101434706B1 KR 1020097019114 A KR1020097019114 A KR 1020097019114A KR 20097019114 A KR20097019114 A KR 20097019114A KR 101434706 B1 KR101434706 B1 KR 101434706B1
Authority
KR
South Korea
Prior art keywords
active ingredient
suspension
average particle
medicinally
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097019114A
Other languages
English (en)
Korean (ko)
Other versions
KR20090117894A (ko
Inventor
야스노리 사토
Original Assignee
아스카 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스카 세이야쿠 가부시키가이샤 filed Critical 아스카 세이야쿠 가부시키가이샤
Publication of KR20090117894A publication Critical patent/KR20090117894A/ko
Application granted granted Critical
Publication of KR101434706B1 publication Critical patent/KR101434706B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020097019114A 2007-02-16 2008-02-15 미립자 유성 현탁액을 포함하는 의약 조성물 Active KR101434706B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2007-035916 2007-02-16
JP2007035916 2007-02-16
PCT/JP2008/000230 WO2008099615A1 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物

Publications (2)

Publication Number Publication Date
KR20090117894A KR20090117894A (ko) 2009-11-13
KR101434706B1 true KR101434706B1 (ko) 2014-08-26

Family

ID=39689861

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097019114A Active KR101434706B1 (ko) 2007-02-16 2008-02-15 미립자 유성 현탁액을 포함하는 의약 조성물

Country Status (9)

Country Link
US (1) US8309138B2 (https=)
EP (1) EP2123255B1 (https=)
JP (2) JP4588791B2 (https=)
KR (1) KR101434706B1 (https=)
CN (1) CN101610754A (https=)
AU (1) AU2008215659B2 (https=)
CA (1) CA2677842C (https=)
ES (1) ES2423929T3 (https=)
WO (1) WO2008099615A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
CN103655512B (zh) * 2013-12-12 2015-05-20 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
WO2019022152A1 (ja) 2017-07-26 2019-01-31 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
EP3668957A4 (en) * 2017-08-17 2021-06-02 University of Delaware Furan based compositions and methods of making thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010073226A (ko) * 1998-10-30 2001-07-31 프리돌린 클라우스너, 롤란드 비. 보레르 작은 입자 크기를 갖는 이소트레티노인 조성물 및 이의제조 방법
WO2006070927A1 (ja) * 2004-12-28 2006-07-06 Aska Pharmaceutical Co., Ltd. ピリミジニルイソオキサゾール誘導体

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0548238A1 (en) 1990-09-13 1993-06-30 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
ES2183935T3 (es) 1995-02-13 2003-04-01 Searle & Co Isoxazoles sustituidos para el tratamiento de la inflamacion.
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
RU2186562C2 (ru) 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
PL337020A1 (en) 1997-05-22 2000-07-31 Searle & Co Substituted pyrazoles as kinase p38 inhibitors
CA2320087C (en) 1998-02-09 2006-12-19 Joel Bolonick Treatment of chronic inflammatory disorders of the gastrointestinal tract
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
DE69911993T2 (de) * 1998-12-23 2004-05-19 Amgen Inc., Thousand Oaks Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
AU765492B2 (en) 1998-12-25 2003-09-18 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
EA004683B1 (ru) 1999-02-23 2004-06-24 Мерк Энд Ко., Инк. Фармацевтическая композиция, содержащая омепразол
WO2000064894A1 (en) 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
CA2386277A1 (en) 1999-10-01 2001-04-12 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
IN192188B (https=) 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
CA2423170A1 (en) 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
AU2002364146A1 (en) 2001-12-20 2003-07-09 Pharmacia Corporation Pharmaceutical suspension for oral administration
DE60319073T2 (de) 2002-03-20 2009-02-05 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
CA2492112A1 (en) 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003255844A1 (en) 2002-08-23 2004-03-11 Ionix Pharmaceuticals Limited Five-membered heterocyclic compounds in the treatment of chronic and acute pain
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
US20040132755A1 (en) 2002-09-06 2004-07-08 Mark Ledeboer Isoxazoles and uses thereof
PT1605956E (pt) 2002-12-18 2016-03-09 Centrexion Therapeutics Corp Administração de capsaicinóides para o tratamento da osteoartrite
PL378111A1 (pl) 2003-02-14 2006-03-06 Smithkline Beecham Corporation Nowe związki
CA2515190A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
JPWO2004073692A1 (ja) 2003-02-18 2006-06-01 山下　伸二 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
WO2005013938A1 (ja) 2003-08-06 2005-02-17 Eisai Co., Ltd. 薬物超微粒子の製造法及び製造装置
JP5096658B2 (ja) 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
KR100843526B1 (ko) 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 피라졸의 접합 유도체
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
DK1742618T3 (da) 2004-05-04 2012-10-01 Hormos Medical Ltd Flydende orale formuleringer af ospemifen
JP2007039408A (ja) 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010073226A (ko) * 1998-10-30 2001-07-31 프리돌린 클라우스너, 롤란드 비. 보레르 작은 입자 크기를 갖는 이소트레티노인 조성물 및 이의제조 방법
WO2006070927A1 (ja) * 2004-12-28 2006-07-06 Aska Pharmaceutical Co., Ltd. ピリミジニルイソオキサゾール誘導体

Also Published As

Publication number Publication date
US8309138B2 (en) 2012-11-13
CA2677842A1 (en) 2008-08-21
CN101610754A (zh) 2009-12-23
JP4588791B2 (ja) 2010-12-01
EP2123255A1 (en) 2009-11-25
US20100092565A1 (en) 2010-04-15
JPWO2008099615A1 (ja) 2010-05-27
CA2677842C (en) 2014-09-16
KR20090117894A (ko) 2009-11-13
ES2423929T3 (es) 2013-09-25
EP2123255B1 (en) 2013-05-15
WO2008099615A1 (ja) 2008-08-21
EP2123255A4 (en) 2010-06-02
AU2008215659A1 (en) 2008-08-21
JP2010120974A (ja) 2010-06-03
AU2008215659B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
KR101434706B1 (ko) 미립자 유성 현탁액을 포함하는 의약 조성물
ES2883448T3 (es) Composiciones farmacéuticas mejoradas de pimobendán
KR102694699B1 (ko) 글루코키나제 활성화제를 포함하는 고체 조성물 및 그것의 제조 및 사용 방법
Zhou et al. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine
JP6796132B2 (ja) 液体剤形中の薬学的活性化合物放出性多層微小粒子
KR20220164506A (ko) 건강관리 제품을 위한 계면활성제
JP2011157390A (ja) 胃液において不溶性の微小顆粒、その調製方法、および薬学的調製物
CA2867701C (en) Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
RS20050971A (sr) Emulzioni sistemi koji sadrže derivate azetidina
JPWO2006073154A1 (ja) 医薬組成物及びその製造方法
MX2007007887A (es) Sistema galenico novedoso para transporte del principio activo, metodo de preparacion y uso.
KR101200169B1 (ko) 플루비프로펜을 함유하는 고체 자가 유화 약물 전달 조성물
KR101096429B1 (ko) 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제
CN1615899B (zh) 葛根素口服制剂
Nandal et al. Novel Approaches of Self Emulsifying Drug Delivery Systems and Recent Patents: A Comprehensive Review
TWI597063B (zh) 藥物組成物及其製備方法
JPS6136217A (ja) 経口投与用持効性製剤
CN121311218A (zh) 雌激素受体降解剂的固体口服剂型
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
McDonald Development of an oral drug delivery platform formulation for the targeted delivery of celecoxib for the chemoprevention and treatment of colorectal cancer.
JPS607601B2 (ja) 医薬用カプセル基剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090914

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130102

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140128

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140721

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140820

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140820

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170811

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170811

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20200807

Start annual number: 7

End annual number: 7